Adma Biologics (ADMA) Cost of Revenue (2011 - 2025)

Adma Biologics' Cost of Revenue history runs 13 years deep, the most recent figure standing at -$162.2 million for Q4 2025.

• Quarterly Cost of Revenue fell 179.55% year-over-year to -$162.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$47.6 million (down 117.88% YoY) and the FY2025 annual result came in at $4.8 million, down 97.66% from the prior year.
• Cost of Revenue was -$162.2 million for Q4 2025 at Adma Biologics, down from $58.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $203.9 million in Q4 2024 and bottomed at -$162.2 million in Q4 2025.
• A 5-year average of $22.1 million and a median of $3.0 million in 2021 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2021 — Cost of Revenue slumped 333.42% — and 2024, when it jumped 12786.51%.
• Adma Biologics' Cost of Revenue stood at -$44.6 million in 2021, then surged by 180.26% to $35.8 million in 2022, then jumped by 362.76% to $165.7 million in 2023, then rose by 23.08% to $203.9 million in 2024, then tumbled by 179.55% to -$162.2 million in 2025.
• Business Quant data shows ADMA's Cost of Revenue at -$162.2 million in Q4 2025, $58.6 million in Q3 2025, and $54.8 million in Q2 2025.